Alternating Osimertinib and Gefitinib as Second-Line Treatment for EGFR-Mutated NSCLC Harbouring a T790M Resistance Mutation (OSCILLATE)

被引：0
|
作者：
Solomon, B. [1 ]
Mersiades, A. [2 ]
Brown, C. [2 ]
Dawson, S. [1 ]
Wong, S. [1 ]
Tan, L. [3 ]
Yip, S. [2 ]
Cheung, Y. [2 ]
Jurkovic, H. [2 ]
Walker, M. [2 ]
Kao, S. [4 ]
Lee, C. K. [5 ]
Newnham, G. [6 ]
O'Byrne, K. [7 ]
Parakh, S. [8 ]
Jasas, K. [9 ]
Bray, V. [10 ]
Stockler, M. [2 ]
John, T. [3 ]
Pavlakis, N. [11 ]
机构：
[1] Peter MacCallum Canc Ctr, Div Res, Melbourne, Vic, Australia
[2] Univ Sydney, Nhmrc Clin Trials Ctr, Sydney, NSW, Australia
[3] Peter MacCallum Canc Ctr, Dept Med Oncol, Melbourne, Vic, Australia
[4] Chris OBrien Lifehouse, Dept Med Oncol, Sydney, NSW, Australia
[5] St George Hosp, Dept Med Oncol, Sydney, ACT, Australia
[6] St Vincents Hosp, Dept Med Oncol, Melbourne, Vic, Australia
[7] Princess Alexandra Hosp, Dept Med Oncol, Brisbane, Qld, Australia
[8] Austin Hosp, Dept Med Oncol, Melbourne, Vic, Australia
[9] Sir Charles Gairdner Hosp, Dept Med Oncol, Perth, WA, Australia
[10] Liverpool Hosp, Dept Med Oncol, Sydney, NSW, Australia
[11] Royal North Shore Hosp, Dept Med Oncol, Sydney, NSW, Australia
来源：
JOURNAL OF THORACIC ONCOLOGY | 2021年 / 16卷 / 03期
关键词：
EGFR-mutated NSCLC; T790M resistance mutation; osimertinib;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P76.64
引用
收藏
页码：S615 / S616
页数：2
相关论文
共 50 条
  • [21] Loss of T790M mutation is associated with early progression to osimertinib in Chinese patients with advanced NSCLC who are harboring EGFR T790M
    Zhao, Sha
    Li, Xuefei
    Zhao, Chao
    Jiang, Tao
    Jia, Yijun
    Shi, Jinpeng
    He, Yayi
    Li, Jiayu
    Zhou, Fei
    Gao, Guanghui
    Li, Wei
    Chen, Xiaoxia
    Su, Chunxia
    Ren, Shengxiang
    Zhou, Caicun
    LUNG CANCER, 2019, 128 : 33 - 39
  • [22] Dynamic mutation profiles of Chinese patients with EGFR T790M advanced NSCLC receiving osimertinib
    Zhang, X.
    Wu, Y-L.
    Chen, Y.
    Zhang, H.
    Wu, G.
    Lu, Y.
    Liang, Z.
    Hu, Y.
    Cheng, Y.
    Wang, J.
    Ying, J.
    Liu, W.
    Liang, Z.
    ANNALS OF ONCOLOGY, 2022, 33 : S1537 - S1537
  • [23] EGFR T790M Mutation Detection and Osimertinib Treatment Response Evaluation by Liquid Biopsy in Advanced NSCLC Patients
    Li, C.
    Liu, H.
    Zhang, B.
    Zhang, Z.
    Su, Y.
    Wang, C.
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S2141 - S2142
  • [24] Optimizing Sequential Treatment With EGFR Tyrosine Kinase Inhibitor With a Simulation of the T790M Mutation Rate in EGFR-Mutated Lung Cancer
    Haratake, Naoki
    Misumi, Toshihiro
    Yamanaka, Takeharu
    Seto, Takashi
    JTO CLINICAL AND RESEARCH REPORTS, 2020, 1 (04):
  • [25] Osimertinib alone as second-line treatment for brain metastases (BM) control may be more limited than for non-BM in advanced NSCLC patients with an acquired EGFR T790M mutation
    Li, Changhui
    Nie, Wei
    Guo, Jingdong
    Xiong, Anning
    Zhong, Hua
    Chu, Tianqing
    Zhong, Runbo
    Xu, Jianlin
    Lu, Jun
    Zheng, Xiaoxuan
    Zhang, Bo
    Shen, Yinchen
    Pan, Feng
    Han, Baohui
    Zhang, Xueyan
    RESPIRATORY RESEARCH, 2021, 22 (01)
  • [26] Highly Sensitive Detection of EGFR T790M Mutation in Pre-TKI Specimens of EGFR-Mutated NSCLC: In Cis, In Trans, or a Different Clone?
    Leone, Alvaro
    JOURNAL OF THORACIC ONCOLOGY, 2013, 8 (03) : E26 - E27
  • [27] Osimertinib alone as second-line treatment for brain metastases (BM) control may be more limited than for non-BM in advanced NSCLC patients with an acquired EGFR T790M mutation
    Changhui Li
    Wei Nie
    Jingdong Guo
    Anning Xiong
    Hua Zhong
    Tianqing Chu
    Runbo Zhong
    Jianlin Xu
    Jun Lu
    Xiaoxuan Zheng
    Bo Zhang
    Yinchen Shen
    Feng Pan
    Baohui Han
    Xueyan Zhang
    Respiratory Research, 22
  • [28] Targeting EGFR T790M mutation in NSCLC: From biology to evaluation and treatment
    Passaro, Antonio
    Guerini-Rocco, Elena
    Pochesci, Alessia
    Vacirca, Davide
    Spitaleri, Gianluca
    Catania, Chiara Matilde
    Rappa, Alessandra
    Barberis, Massimo
    de Marinis, Filippo
    PHARMACOLOGICAL RESEARCH, 2017, 117 : 406 - 415
  • [29] A Prospective Observational Study of Osimertinib Using Plasma Concentrations in NSCLC With Acquired EGFR T790M Mutation
    Nakagawa, T.
    Fukuhara, T.
    Imai, K.
    Igusa, R.
    Yokota, H.
    Watanabe, K.
    Suzuki, A.
    Morita, M.
    Inoue, A.
    Miura, M.
    Minamiya, Y.
    Maemondo, M.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (10) : S953 - S954
  • [30] ASTRIS a RWT with Osimertinib in NSCLC EGFR T790M Mutated: Disease Characteristics from Patients Included in Argentina
    Biolchi, M.
    Recondo, G.
    Casalnuovo, M.
    Tsou, F.
    Diaz Perez, I.
    Reinhold, F.
    Martin, C.
    JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (09) : S169 - S169
12345